Related Experiment Video
Updated: Mar 29, 2026
Innovative Adipose Tissue Fractionation for Transforming Fat into Specialized Components
Published on: July 11, 2025
Volumizing Hyaluronic Acid Filler for Midface Volume Deficit: Results After Repeat Treatment
Leslie Baumann1, Rhoda S Narins, Kenneth Beer
1*Baumann Cosmetic and Research Institute, Miami, Florida; †Dermatology Surgery and Laser Center, New York, New York; ‡Beer Cosmetic, Surgical and General Dermatology, West Palm Beach and Jupiter, Florida; §The Westmount Institute of Plastic Surgery, Montreal, QC, Canada; ‖Cosmetic Laser Dermatology, San Diego, California; ¶Clinical Professor of Surgery, Division of Plastic Surgery, University of Chicago Pritzker School of Medicine, The Few Institute for Aesthetic Plastic Surgery, Chicago, Illinois; #Suffield, Connecticut; **Allergan plc, Irvine, California.
Background:
Juvéderm Voluma XC (VYC-20L; hyaluronic acid gel) is approved in the United States for correction of age-related midface volume deficit (MVD).
Objective:
Assess safety and effectiveness of VYC-20L after repeat treatment.
Methods:
Subjects with MVD underwent optional repeat treatment 12 to 24 months after initial treatment if correction was lost or at 24 months regardless of loss of correction (n = 167). Investigators rated outcomes on the Mid-Face Volume Deficit Scale (MFVDS) and the Global Aesthetic Improvement Scale (GAIS). Subject-rated outcomes were the GAIS, overall satisfaction with facial appearance, achievement of treatment goal, and Self-Perception of Age questionnaire. Subjects recorded treatment-site responses in 30-day diaries.
Results:
Mean injection volume for repeat treatment (3.13 mL) was approximately half the mean total injection volume for initial/touch-up treatment (6.8 mL). After repeat treatment, effectiveness was demonstrated on all investigator-rated and subject-rated measures, consistent with results observed after initial treatment. The percentage of subjects improving by ≥1 point on the MFVDS was 82.8% and 91.1% at 6 and 12 months after repeat treatment, respectively. The incidence, severity, and duration of common treatment-site responses were lower after repeat versus initial treatment.
Conclusion:
Repeat treatment with VYC-20L was well tolerated and resulted in high levels of effectiveness and subject satisfaction.
